An analysis by an independent statistician of the ongoing Phase 3 trial for Larazotide has concluded that a substantial number of new patients would have to be added to the existing trial in order to get scientifically meaningful results.
Continue ReadingOn August 13th, 2019, Innovate Biopharmaceuticals, Inc. (Innovate) announced the first patient has been dosed in its Phase 3 clinical trial for patients with celiac disease. The CeD LA 3001…
Continue ReadingLast month, the Celiac Disease Foundation had the privilege of sponsoring the 2024 International Celiac Disease Symposium in Sheffield, UK. As the first patient advocate invited to chair and present on a scientific panel, CEO Marilyn Geller co-chaired the End Points in Clinical Trials session with Dr. Francisco Leon, CEO...